HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.

AbstractOBJECTIVE:
To determine the prevalence of valvular heart disease in a cohort of patients taking cabergoline for the management of hyperprolactinemia.
METHODS:
A retrospective review of medical records identified patients with hyperprolactinemia who underwent evaluation at Vanderbilt University Medical Center between January and June 2007. The medical records of those patients who were prescribed cabergoline and who underwent elective echocardiography were reviewed for details pertaining to cardiac valvular abnormalities and cabergoline use.
RESULTS:
Forty-five patients (mean age, 41 +/- 10 years [SD]) taking 0.91 +/- 0.96 mg of cabergoline per week for a mean duration of 39 +/- 29 months underwent echocardiography. Abnormalities of the cardiac valves were present in 3 patients (7%): 1 patient exhibited mild mitral regurgitation, 1 patient had focal aortic valve thickening, and 1 patient demonstrated mitral valve thickening. We found no significant difference in either the cumulative dose of cabergoline (P = .800) or the duration of cabergoline therapy (P = .745) between those patients with and those without these echocardiographic abnormalities.
CONCLUSION:
We found echocardiographic valve abnormalities in 3 of 45 patients (7%) who had been prescribed cabergoline for the management of hyperprolactinemia. This prevalence of valvular heart disease after approximately 3 years of cabergoline treatment is no different from that previously reported in normal populations as determined by echocardiography.
AuthorsJessica K Devin, Vipul T Lakhani, Benjamin F Byrd 3rd, Lewis S Blevins Jr
JournalEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (Endocr Pract) Vol. 14 Issue 6 Pg. 672-7 (Sep 2008) ISSN: 1934-2403 [Electronic] United States
PMID18996784 (Publication Type: Journal Article)
Chemical References
  • Ergolines
  • Cabergoline
Topics
  • Adult
  • Cabergoline
  • Cohort Studies
  • Echocardiography
  • Ergolines (adverse effects, therapeutic use)
  • Female
  • Heart Valve Diseases (chemically induced)
  • Humans
  • Hyperprolactinemia (drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: